Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 13, 2022, the board of directors of
P3 Health Partners Inc. (“TopCo”) and its subsidiary, P3 Health Group Management, LLC (together with TopCo, the “Company”)
approved entering into employment agreements (the “Employment Agreements”) and transaction bonus agreements (the “Transaction
Bonus Agreements”) with Sherif Abdou (Founder and Chief Executive Officer) and Amir Bacchus (Founder and Chief Medical Officer)
(each, an “Executive”).
Employment Agreements
The Employment Agreements supersede the employment
agreements that Drs. Abdou and Bacchus previously entered into.
The initial term of each Employment Agreement will
end on January 1, 2025, and the term automatically will renew for successive one-year terms unless advance written notice of non-renewal
is given by either party (such term, the "employment term"). In addition, during the employment term, for so long as Dr. Abdou
or Dr. Bacchus serve as Chief Executive Officer or Chief Medical Officer, respectively, of TopCo, TopCo will nominate the Executive
for re-election as a member of the Board. Under the Employment Agreements, Dr. Abdou reports to the TopCo board of directors and
Dr. Bacchus reports to the TopCo chief executive officer.
The Employment Agreements provide for an annual
base salary ($800,000 in the case of Dr. Abdou and $600,000 in the case of Dr. Bacchus) and eligibility to earn an annual bonus
targeted at 100% of the Executive’s annual base salary. The Executives are entitled to participate in any employee benefit plan
that the Company adopts, and the Company has agreed to maintain short-term and long-term disability insurance coverage for Drs. Abdou
and Bacchus during the term of their respective employment.
Under the Employment Agreements, if the Executive’s
employment is terminated without “cause” by the Company or by the Executive for “cause” (each, as defined in the
Employment Agreements), then, in addition to any accrued amounts, the Executive will be entitled to receive the following severance payments
and benefits, subject to the Executive’s and the Company’s timely execution (and non-revocation) of a mutual release of claims:
| · | Cash severance in an aggregate amount equal to one-and-one-half times the sum of the Executive’s (i) annual base salary
then in effect and (ii) target annual bonus amount, payable in equal installments over an 18-month period following the date of termination. |
| · | Company-subsidized COBRA premiums for up to 18 months. |
If the Executive’s employment is terminated
without “cause” by the Executive, then, in addition to any accrued amounts, the Executive will be entitled to receive cash
severance in an aggregate amount equal to one-and-one-half times the sum of the Executive’s (i) annual base salary then in
effect and (ii) target annual bonus amount, payable in equal installments over an 18-month period following the date of termination.
In addition, if the Executive’s employment
is terminated due to his death, then, in addition to any accrued amounts, the Executive will be entitled to receive a pro-rated portion
of his target bonus for the year of termination.
The Employment Agreements contain customary confidentiality
and mutual nondisparagement provisions, as well as a standard non-compete restriction effective during employment and for 18 months thereafter
and service provider/customer non-solicitation restrictions effective during employment and for 24 months thereafter.
The foregoing description of the Employment Agreements
with Drs. Abdou and Bacchus is not complete and is qualified in its entirety by the terms of the applicable agreement, copies of
which are filed herewith as Exhibit 10.1 and 10.2, respectively, and incorporated herein by reference.
Transaction Bonus Agreements
The Transaction Bonus Agreements provide for the
payment of bonuses in an aggregate amount equal to $6,300,000 (Dr. Abdou) and $3,700,000 (Dr. Bacchus) in connection with the
consummation of the business combination that resulted in TopCo becoming the sole managing member of P3 Health Group, LLC (each, a “Transaction
Bonus”).
Pursuant to the Transaction Bonus Agreements, the
first installment of the Transaction Bonus ($3,300,000 for Dr. Abdou and $1,700,000 for Dr. Bacchus) will be paid within five
days following the execution of the Transaction Bonus Agreement. The second installment of the Transaction Bonus ($3,000,000 for Dr. Abdou,
and $2,000,000 for Dr. Bacchus) (the “Second Installment”) will be paid on December 15, 2022. The Second Installment
will not be paid if the Executive’s employment is terminated for “cause” by the Company or without “cause”
by the Executive prior to the payment date. If the Executive fails to comply with the Transaction Bonus Terms (as described below), the
Executive will be required to repay the Transaction Bonus (or forfeit any portion of the Transaction Bonus that has not yet been paid).
The Transaction Bonus Terms include: (i) a
restriction on the Executive’s ability to offer, sell, or announce an intention to dispose of any shares of the Company’s
Class A common stock until the closing of the Company’s first underwritten offering and sale of common stock (the “First
Secondary Sale”); (ii) a requirement that, following the First Secondary Sale, the Executive only sell shares of the Company’s
Class A common stock pursuant to a customary 10b5-1 plan; and (iii) a limitation on the number of shares of Class A common
stock the Executive may sell under such 10b5-1 plan. These restrictions apply to Class A common stock held directly by the Executive
or in a trust established by the Executive.
The foregoing description of the Transaction Bonus
Agreements with Drs. Abdou and Bacchus is not complete and is qualified in its entirety by the terms of the applicable agreement,
copies of which are filed herewith as Exhibit 10.3 and 10.4, respectively, and incorporated herein by reference.